INLYTA (Axitinib)

INLYTA (Axitinib)

Regular price
$1,539.99 USD
Sale price
$1,539.99 USD
Regular price
Sold out
Unit price
Shipping calculated at checkout.


What is this medication?

INLYTA (Axitinib)
Antineoplastic Agent, Tyrosine Kinase Inhibitor, Vascular Endothelial Growth Factor (VEGF) Inhibitor

INLYTA (Axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.

How does this medication work?

INLYTA (Axitinib) is a tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGF) inducing apoptosis of cancer cells and suppressing tumor growth, angiogenesis and metastasis.

How should I take this medication?

Renal cell carcinoma, first-line combination therapy:
Oral: In combination with Avelumab, take 5 mg twice daily as an initial dose. Increase the dose if tolerated.

Oral: In combination with Pembrolizumab, take 5 mg twice daily as an initial dose. Increase the dose if tolerated.

Renal cell carcinoma, second-line single-agent therapy:
Oral: Take 5 mg twice daily. Increase the dose if tolerated.

How to Take: May administer with or without food. Swallow tablets whole with a full glass of water. Do not crush, split, or chew dosage form.

What should I watch for while using this medication?

Before starting INLYTA (Axitinib), make sure your physician is aware of any allergies or medications you currently take, if you are pregnant, or breastfeeding. Axitinib use has been associated with rare but serious adverse events such as cardiotoxicity, GI perforation/fistula, hemorrhage, hepatotoxicity, hypertension, posterior reversible encephalopathy syndrome, proteinuria, thrombotic events, thyroid disorders, and wound healing complications.  Blood pressure needs to be monitored and treated as needed.  If hypertension persists, consider reducing the dose of Axitinib.  Gastrointestinal perforation and fistula, including death, have occurred.  Use Axitinib  with caution in patients at risk for gastrointestinal perforation or fistula.  Monitor thyroid function before initiation of, and periodically throughout, treatment with Axitinib. Monitor for proteinuria before initiation of, and periodically throughout, treatment with Axitinib. For moderate to severe proteinuria, reduce the dose or temporarily interrupt treatment with Axitinib. Liver enzyme elevation has been observed. Monitor ALT, AST and bilirubin before initiation of, and periodically throughout treatment.

What if I miss a dose?

If you miss a dose of medication, try to take it as soon as possible.  However, if it is almost time for your next dose, take only that scheduled dose.  Do not take double or extra doses.

How should I store this medication?

Keep out of the reach of children at all times.  Store at room temperature, 59 to 86° F (15 to 30° C).  Protect from light.  Keep the container tightly closed.  Properly dispose of any unused medication after the expiration date.

What are the possible side effects of using this medication?

Hypertension, Palmar-plantar erythrodysesthesia, skin rash, decreased serum bicarbonate, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hyponatremia, hypophosphatemia, hypothyroidism, weight loss, abdominal pain, constipation, decreased appetite, diarrhea, dysgeusia, increased serum amylase, increased serum lipase, mucosal swelling, nausea, stomatitis, vomiting, proteinuria, decreased absolute lymphocyte count, decreased platelet count, decreased white blood cell count, hemorrhage, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, fatigue, headache, voice disorder, arthralgia, asthenia, limb pain, increased serum creatinine, cough, dyspnea, pruritusxeroderma, dyspepsia, upper abdominal pain, increased hemoglobin, myalgia, dizziness.

Note this is not a complete list of side effects for INLYTA (Axitinib), only common ones.